Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. / Ryom, Lene; Dilling Lundgren, Jens; Reiss, Peter; Kirk, Ole; Law, Matthew; Ross, Mike; Morlat, Phillip; Andreas Fux, Christoph; Fontas, Eric; De Wit, Stephane; D'Arminio Monforte, Antonella; El-Sadr, Wafaa; Phillips, Andrew; Ingrid Hatleberg, Camilla; Sabin, Caroline; Mocroft, Amanda; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group.

I: The Journal of Infectious Diseases, Bind 220, Nr. 10, 2019, s. 1629-1634.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ryom, L, Dilling Lundgren, J, Reiss, P, Kirk, O, Law, M, Ross, M, Morlat, P, Andreas Fux, C, Fontas, E, De Wit, S, D'Arminio Monforte, A, El-Sadr, W, Phillips, A, Ingrid Hatleberg, C, Sabin, C, Mocroft, A & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group 2019, 'Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study', The Journal of Infectious Diseases, bind 220, nr. 10, s. 1629-1634. https://doi.org/10.1093/infdis/jiz369

APA

Ryom, L., Dilling Lundgren, J., Reiss, P., Kirk, O., Law, M., Ross, M., Morlat, P., Andreas Fux, C., Fontas, E., De Wit, S., D'Arminio Monforte, A., El-Sadr, W., Phillips, A., Ingrid Hatleberg, C., Sabin, C., Mocroft, A., & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group (2019). Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. The Journal of Infectious Diseases, 220(10), 1629-1634. https://doi.org/10.1093/infdis/jiz369

Vancouver

Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M o.a. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. The Journal of Infectious Diseases. 2019;220(10):1629-1634. https://doi.org/10.1093/infdis/jiz369

Author

Ryom, Lene ; Dilling Lundgren, Jens ; Reiss, Peter ; Kirk, Ole ; Law, Matthew ; Ross, Mike ; Morlat, Phillip ; Andreas Fux, Christoph ; Fontas, Eric ; De Wit, Stephane ; D'Arminio Monforte, Antonella ; El-Sadr, Wafaa ; Phillips, Andrew ; Ingrid Hatleberg, Camilla ; Sabin, Caroline ; Mocroft, Amanda ; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. / Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. I: The Journal of Infectious Diseases. 2019 ; Bind 220, Nr. 10. s. 1629-1634.

Bibtex

@article{20fab0c1fb07449da444aff868e4d1d3,

title = "Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study",

abstract = "BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.",

author = "Lene Ryom and {Dilling Lundgren}, Jens and Peter Reiss and Ole Kirk and Matthew Law and Mike Ross and Phillip Morlat and {Andreas Fux}, Christoph and Eric Fontas and {De Wit}, Stephane and {D'Arminio Monforte}, Antonella and Wafaa El-Sadr and Andrew Phillips and {Ingrid Hatleberg}, Camilla and Caroline Sabin and Amanda Mocroft and {Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group}",

year = "2019",

doi = "10.1093/infdis/jiz369",

language = "English",

volume = "220",

pages = "1629--1634",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "10",

}

RIS

TY - JOUR

T1 - Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus

T2 - the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

AU - Ryom, Lene

AU - Dilling Lundgren, Jens

AU - Reiss, Peter

AU - Kirk, Ole

AU - Law, Matthew

AU - Ross, Mike

AU - Morlat, Phillip

AU - Andreas Fux, Christoph

AU - Fontas, Eric

AU - De Wit, Stephane

AU - D'Arminio Monforte, Antonella

AU - El-Sadr, Wafaa

AU - Phillips, Andrew

AU - Ingrid Hatleberg, Camilla

AU - Sabin, Caroline

AU - Mocroft, Amanda

AU - Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

PY - 2019

Y1 - 2019

N2 - BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.

AB - BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.

U2 - 10.1093/infdis/jiz369

DO - 10.1093/infdis/jiz369

M3 - Journal article

C2 - 31504669

VL - 220

SP - 1629

EP - 1634

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -

ID: 237753708